Product liability litigation regularly involves the highest stakes in cases of extreme complexity. Faced with such franchise-threatening matters, the world’s leading corporations trust Paul, Weiss to lead them to victory. Our superior ability to establish a winning, long-term strategy, our unique skill at breaking down and presenting complicated material, and our vaunted trial prowess make us counsel of choice in many of the most important product liability lawsuits.
Client News
JM Eagle Prevails in High-Stakes FCA Case
Paul, Weiss prevailed in a high-stakes False Claims Act damages lawsuit against our client, JM Eagle, when a judge issued a judgment as a matter of law and dismissed the case.
» moreClient News
AbbVie Achieves Complete Defense Verdict
See Also
Paul, Weiss achieved a complete defense verdict for AbbVie Inc. in a products liability suit relating to AbbVie’s testosterone replacement therapy, concluding a two week trial in state court in Cook County, Illinois.
» moreClient News
Pfizer Achieves Trial Victory in Second Zoloft Birth Defects Case
See Also
Paul, Weiss client Pfizer achieved a major victory in the second Zoloft birth defects case to go to trial in the U.S. At the conclusion of an eight-day trial, a Philadelphia jury returned a complete defense verdict and concluded that Pfizer's warnings about the risks of Zoloft were adequate.
» moreClient News
Pfizer Wins First U.S. Trial Over Zoloft Birth-Defect Risk
See Also
As reported in Bloomberg, Reuters and other media outlets, Paul, Weiss client Pfizer achieved a major victory in the first Zoloft birth defects case to go to trial in the U.S. At the conclusion of a seven-day trial, a St. Louis jury returned a complete defense verdict in under two hours. The jury rejected the plaintiff's allegations that a mother's use of Zoloft in the first trimester of her pregnancy caused her child's cardiac birth defect.
» moreClient News
Pfizer Wins Dismissal of Shareholder Class Action Suit
As reported by Thomson Reuters and Law.com, Paul, Weiss client Pfizer Inc. achieved a major victory when a federal court granted the company's motion for summary judgment in In Re Pfizer Inc. Securities Litigation, a securities class action filed in the United States District Court for the Southern District of New York involving decade-old disclosures related to Celebrex and Bextra.
» more